BeyondSpring Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BYSI research report →
Companywww.beyondspringpharma.com
BeyondSpring Inc. , a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer.
- CEO
- Lan Huang
- IPO
- 2017
- Employees
- 40
- HQ
- Florham Park, NY, US
Price Chart
Valuation
- Market Cap
- $59.21M
- P/E
- -7.75
- P/S
- 0.00
- P/B
- -1.72
- EV/EBITDA
- -6.63
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 23.76%
- ROIC
- -136.37%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-7,992,000 · 28.15%
- EPS
- $-0.20 · 28.57%
- Op Income
- $-8,945,000
- FCF YoY
- -20.44%
Performance & Tape
- 52W High
- $3.44
- 52W Low
- $1.18
- 50D MA
- $1.61
- 200D MA
- $1.74
- Beta
- 0.41
- Avg Volume
- 17.98K
Get TickerSpark's AI analysis on BYSI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 20, 26 | Huang Lan | other | 260,582 |
| Apr 1, 26 | Kirkby Matthew | other | 23,902 |
| Apr 1, 26 | Fabbio Patrick | other | 22,165 |
| Apr 1, 26 | Delaney Brendan | other | 20,427 |
| Apr 1, 26 | Majeti Jiangwen | other | 21,730 |
| Apr 1, 26 | Lu Yingjuan June | other | 17,840 |
| Apr 1, 26 | Huang Lan | other | 11,514 |
| Apr 1, 26 | Xu Sihai | other | 18,689 |
| Oct 16, 25 | Decheng Capital China Life Sciences USD Fund III, L.P. | sell | 85,798 |
| Oct 17, 25 | Decheng Capital China Life Sciences USD Fund III, L.P. | sell | 45,513 |
Our BYSI Coverage
We haven't published any research on BYSI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BYSI Report →